Publications by authors named "Yi-Rui Stefanie Wang"
Article Synopsis
- Hepatocellular carcinoma (HCC) is a major cause of cancer deaths, and Sorafenib was the only FDA-approved treatment for advanced cases until recently, highlighting the need for new therapies.
- This study developed a zebrafish drug screening platform to compare two new drugs, 419S1 and 420S1, with Sorafenib, finding that all three have anti-angiogenesis properties but 419S1 resulted in lower toxicity to both the liver and embryos.
- Ultimately, 419S1 and 420S1 showed better effectiveness in halting liver cancer growth compared to Sorafenib, suggesting the zebrafish model can aid in discovering safer and more effective treatments for HCC and personalized medicine
